// App-Quantinova.ai

4676 : Overcoming EGFR-induced resistance to enzalutamide in castration-resistant prostate cancer

Researchers

Presenter

  • Thomas M. Steele

Principal Investigators

  • Maitreyee K. Jathal

  • Salma Siddiqui

  • Paramita M. Ghosh

Medical Centers

  • UC Davis Medical Center, Sacramento, CA

  • VA Northern California Healthcare System, Mather, CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Nucleoside diphosphate kinase A

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Enzalutamide

  • dacomitinib

  • Erlotinib hydrochloride

  • Lapatinib

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved